Personalized Mapping of Drug Metabolism by the Human Gut Microbiome

生物 微生物群 基因组 肠道微生物群 计算生物学 背景(考古学) 药物代谢 药物开发 个性化医疗 人体微生物群 药品 生物信息学 遗传学 基因 药理学 古生物学
作者
Bahar Javdan,Jaime G Lopez,Pranatchareeya Chankhamjon,Ying-Chiang Jeffrey Lee,Raphaella Hull,Qihao Wu,Xiaojuan Wang,Seema Chatterjee,Mohamed S. Donia
出处
期刊:Cell [Cell Press]
卷期号:181 (7): 1661-1679.e22 被引量:502
标识
DOI:10.1016/j.cell.2020.05.001
摘要

•Development of subject-personalized ex vivo batch cultures of the gut microbiome•Discovery of diverse drug-microbiome interactions using MDM-Screen•MDM-Screen quantifies drug metabolism by personalized gut microbial communities•Functional genomic and metagenomic screens identify drug-metabolizing enzymes The human gut microbiome harbors hundreds of bacterial species with diverse biochemical capabilities. Dozens of drugs have been shown to be metabolized by single isolates from the gut microbiome, but the extent of this phenomenon is rarely explored in the context of microbial communities. Here, we develop a quantitative experimental framework for mapping the ability of the human gut microbiome to metabolize small molecule drugs: Microbiome-Derived Metabolism (MDM)-Screen. Included are a batch culturing system for sustained growth of subject-specific gut microbial communities, an ex vivo drug metabolism screen, and targeted and untargeted functional metagenomic screens to identify microbiome-encoded genes responsible for specific metabolic events. Our framework identifies novel drug-microbiome interactions that vary between individuals and demonstrates how the gut microbiome might be used in drug development and personalized medicine. The human gut microbiome harbors hundreds of bacterial species with diverse biochemical capabilities. Dozens of drugs have been shown to be metabolized by single isolates from the gut microbiome, but the extent of this phenomenon is rarely explored in the context of microbial communities. Here, we develop a quantitative experimental framework for mapping the ability of the human gut microbiome to metabolize small molecule drugs: Microbiome-Derived Metabolism (MDM)-Screen. Included are a batch culturing system for sustained growth of subject-specific gut microbial communities, an ex vivo drug metabolism screen, and targeted and untargeted functional metagenomic screens to identify microbiome-encoded genes responsible for specific metabolic events. Our framework identifies novel drug-microbiome interactions that vary between individuals and demonstrates how the gut microbiome might be used in drug development and personalized medicine. The oral route is the most common route for drug administration. Upon exiting the stomach, drugs can be absorbed in the small and/or large intestine to reach systemic circulation and eventually the liver or directly transported there via the portal vein. In the liver, drugs may be metabolized and secreted back to the intestines through bile—via enterohepatic circulation (Kimura et al., 1994Kimura T. Sudo K. Kanzaki Y. Miki K. Takeichi Y. Kurosaki Y. Nakayama T. Drug absorption from large intestine: physicochemical factors governing drug absorption.Biol. Pharm. Bull. 1994; 17: 327-333Crossref PubMed Scopus (44) Google Scholar, Li and Jia, 2013Li H. Jia W. Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity.Clin. Pharmacol. Ther. 2013; 94: 574-581Crossref PubMed Scopus (59) Google Scholar). Even parenterally administered drugs and their metabolites can reach the intestines through biliary secretion. Thus, whether prior to or after absorption, some administered drugs will spend a considerable amount of time in the small and large intestines, where our human gut microbiome resides. It is therefore important to study gut microbiome composition and function, specifically as it relates to drug interactions, while accounting for the significant variability between individuals (Falony et al., 2016Falony G. Joossens M. Vieira-Silva S. Wang J. Darzi Y. Faust K. Kurilshikov A. Bonder M.J. Valles-Colomer M. Vandeputte D. et al.Population-level analysis of gut microbiome variation.Science. 2016; 352: 560-564Crossref PubMed Scopus (823) Google Scholar). Broadly speaking, the microbiome interacts with drugs both directly and indirectly. Indirect interactions include competition between microbiome-derived metabolites and administered drugs for the same host metabolizing enzymes (Clayton et al., 2009Clayton T.A. Baker D. Lindon J.C. Everett J.R. Nicholson J.K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism.Proc. Natl. Acad. Sci. USA. 2009; 106: 14728-14733Crossref PubMed Scopus (514) Google Scholar), microbiome effects on the immune system in anticancer immunotherapy (Iida et al., 2013Iida N. Dzutsev A. Stewart C.A. Smith L. Bouladoux N. Weingarten R.A. Molina D.A. Salcedo R. Back T. Cramer S. et al.Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.Science. 2013; 342: 967-970Crossref PubMed Scopus (970) Google Scholar, Sivan et al., 2015Sivan A. Corrales L. Hubert N. Williams J.B. Aquino-Michaels K. Earley Z.M. Benyamin F.W. Lei Y.M. Jabri B. Alegre M.L. et al.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.Science. 2015; 350: 1084-1089Crossref PubMed Scopus (1489) Google Scholar, Vétizou et al., 2015Vétizou M. Pitt J.M. Daillère R. Lepage P. Waldschmitt N. Flament C. Rusakiewicz S. Routy B. Roberti M.P. Duong C.P. et al.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.Science. 2015; 350: 1079-1084Crossref PubMed Scopus (1361) Google Scholar), microbiome reactivation of secreted inactive metabolites of the drug (Wallace et al., 2010Wallace B.D. Wang H. Lane K.T. Scott J.E. Orans J. Koo J.S. Venkatesh M. Jobin C. Yeh L.A. Mani S. Redinbo M.R. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme.Science. 2010; 330: 831-835Crossref PubMed Scopus (507) Google Scholar), and overall microbiome effects on the levels of metabolizing enzymes in the liver and intestine (Meinl et al., 2009Meinl W. Sczesny S. Brigelius-Flohé R. Blaut M. Glatt H. Impact of gut microbiota on intestinal and hepatic levels of phase 2 xenobiotic-metabolizing enzymes in the rat.Drug Metab. Dispos. 2009; 37: 1179-1186Crossref PubMed Scopus (66) Google Scholar). Direct interactions include the partial or complete biochemical transformation of a drug into more or less active metabolites by microbiome-derived enzymes (termed herein: Microbiome-Derived Metabolism, or MDM). The human gut microbiome harbors hundreds of bacterial species, encoding an estimated 100 times more genes than the human genome (Qin et al., 2010Qin J. Li R. Raes J. Arumugam M. Burgdorf K.S. Manichanh C. Nielsen T. Pons N. Levenez F. Yamada T. et al.MetaHIT ConsortiumA human gut microbial gene catalogue established by metagenomic sequencing.Nature. 2010; 464: 59-65Crossref PubMed Scopus (6070) Google Scholar). This enormous diversity and richness represent a repertoire of yet-uncharacterized biochemical activities capable of metabolizing ingested chemicals (Bäckhed et al., 2005Bäckhed F. Ley R.E. Sonnenburg J.L. Peterson D.A. Gordon J.I. Host-bacterial mutualism in the human intestine.Science. 2005; 307: 1915-1920Crossref PubMed Scopus (3159) Google Scholar, Koppel et al., 2017Koppel N. Maini Rekdal V. Balskus E.P. Chemical transformation of xenobiotics by the human gut microbiota.Science. 2017; 356: eaag2770Crossref PubMed Scopus (277) Google Scholar). Although MDM has been observed in dozens of examples for the past 50 years, this process is still mostly overlooked in the drug development pipeline where little to no effort is spent on determining the specific role of MDM in pharmacokinetics (Ilett et al., 1990Ilett K.F. Tee L.B. Reeves P.T. Minchin R.F. Metabolism of drugs and other xenobiotics in the gut lumen and wall.Pharmacol. Ther. 1990; 46: 67-93Crossref PubMed Scopus (172) Google Scholar, Li and Jia, 2013Li H. Jia W. Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity.Clin. Pharmacol. Ther. 2013; 94: 574-581Crossref PubMed Scopus (59) Google Scholar, Scheline, 1973Scheline R.R. Metabolism of foreign compounds by gastrointestinal microorganisms.Pharmacol. Rev. 1973; 25: 451-523PubMed Google Scholar, Spanogiannopoulos et al., 2016Spanogiannopoulos P. Bess E.N. Carmody R.N. Turnbaugh P.J. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism.Nat. Rev. Microbiol. 2016; 14: 273-287Crossref PubMed Scopus (321) Google Scholar). This is because of the vast complexity of the microbiome, and overwhelming technical challenge of testing hundreds of drugs against thousands of cultured isolates under multiple conditions. In contrast to liver-derived metabolism, we lack a systematic and standardized map of MDM, hindering our ability to reliably predict and eventually interfere with undesired microbiome effects on drug pharmacokinetics and pharmacodynamics. To address this gap in knowledge, we developed a quantitative experimental workflow for mapping MDM of orally administered drugs using personalized gut microbiome-derived microbial communities (MDM-Screen). The methods and findings reported here provide a framework for discovering and characterizing novel cases of MDM and for potentially incorporating an “MDM module” in the drug development pipeline. A major challenge in studying the capacity of the human gut microbiome to metabolize orally administered drugs is the diversity of bacterial species and strains involved (Almeida et al., 2019Almeida A. Mitchell A.L. Boland M. Forster S.C. Gloor G.B. Tarkowska A. Lawley T.D. Finn R.D. A new genomic blueprint of the human gut microbiota.Nature. 2019; 568: 499-504Crossref PubMed Scopus (309) Google Scholar, Lloyd-Price et al., 2017Lloyd-Price J. Mahurkar A. Rahnavard G. Crabtree J. Orvis J. Hall A.B. Brady A. Creasy H.H. McCracken C. Giglio M.G. et al.Strains, functions and dynamics in the expanded Human Microbiome Project.Nature. 2017; 550: 61-66Crossref PubMed Scopus (406) Google Scholar, Nayfach et al., 2019Nayfach S. Shi Z.J. Seshadri R. Pollard K.S. Kyrpides N.C. New insights from uncultivated genomes of the global human gut microbiome.Nature. 2019; 568: 505-510Crossref PubMed Scopus (151) Google Scholar, Pasolli et al., 2019Pasolli E. Asnicar F. Manara S. Zolfo M. Karcher N. Armanini F. Beghini F. Manghi P. Tett A. Ghensi P. et al.Extensive Unexplored Human Microbiome Diversity Revealed by Over 150,000 Genomes from Metagenomes Spanning Age, Geography, and Lifestyle.Cell. 2019; 176: 649-662Abstract Full Text Full Text PDF PubMed Scopus (326) Google Scholar, Qin et al., 2010Qin J. Li R. Raes J. Arumugam M. Burgdorf K.S. Manichanh C. Nielsen T. Pons N. Levenez F. Yamada T. et al.MetaHIT ConsortiumA human gut microbial gene catalogue established by metagenomic sequencing.Nature. 2010; 464: 59-65Crossref PubMed Scopus (6070) Google Scholar). Because it is impractical to systematically screen thousands of isolated strains against hundreds of drugs, previous studies have relied mainly on monocultures of a selected set of representative species. However, gene expression and biochemical transformation profiles vary dramatically between a strain grown in monoculture versus in a mixed community. To address these challenges, we sought to develop an optimized ex vivo mixed culturing system that supports the growth of a large proportion of the species from a given microbiome sample and is amenable to high-throughput (HT) biochemical screens. We began our screening efforts focused on a single microbiome donor (pilot donor, PD). To identify the medium and culturing period that can support the growth of a batch culture whose composition is maximally similar to the original PD microbiome, freshly collected and glycerol-stocked human feces from PD were cultured in 14 different media and sampled daily for four days. We then extracted DNA from all samples, amplified the V4 region of the bacterial 16S rRNA gene, and deeply sequenced the amplicons (Figure 1A). From the sequencing results, amplicon sequence variants (ASVs) were inferred and the taxonomic composition at different levels was determined for each sample (see STAR Methods) (Bokulich et al., 2018Bokulich N.A. Kaehler B.D. Rideout J.R. Dillon M. Bolyen E. Knight R. Huttley G.A. Gregory Caporaso J. Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2's q2-feature-classifier plugin.Microbiome. 2018; 6: 90Crossref PubMed Scopus (700) Google Scholar, Bolyen et al., 2018Bolyen E. Rideout J.R. Dillon M.R. Bokulich N.A. Abnet C. Al-Ghalith G.A. Alexander H. Alm E.J. Arumugam M. Asnicar F. et al.QIIME 2: Reproducible, interactive, scalable, and extensible microbiome data science.PeerJ Preprints. 2018; 6 (e27295v27292)Google Scholar, Callahan et al., 2016Callahan B.J. McMurdie P.J. Rosen M.J. Han A.W. Johnson A.J. Holmes S.P. DADA2: High-resolution sample inference from Illumina amplicon data.Nat. Methods. 2016; 13: 581-583Crossref PubMed Scopus (4617) Google Scholar, McDonald et al., 2012McDonald D. Price M.N. Goodrich J. Nawrocki E.P. DeSantis T.Z. Probst A. Andersen G.L. Knight R. Hugenholtz P. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea.ISME J. 2012; 6: 610-618Crossref PubMed Scopus (2830) Google Scholar). We then quantified the differences between the various media and PD at the family level (using the Jensen-Shannon divergence, DJS), and the variant recovery from PD at the single ASV level. As expected, we observed a great level of variation in both the taxonomic composition and diversity between the different media and culturing periods. Some media led to highly diverse communities that captured portions of the original fecal diversity, while others became dominated almost exclusively by a single family. Among the 14 media commonly used in gut microbiome cultivation efforts (Rettedal et al., 2014Rettedal E.A. Gumpert H. Sommer M.O. Cultivation-based multiplex phenotyping of human gut microbiota allows targeted recovery of previously uncultured bacteria.Nat. Commun. 2014; 5: 4714Crossref PubMed Scopus (71) Google Scholar), we identified one, modified Gifu Anaerobic Medium (mGAM), that supported the growth of a bacterial community most similar in composition and diversity to PD’s (Figures 1B and S1A). At the family level, mGAM cultures largely match the composition of PD, differing primarily in a commonly observed expansion of the facultative anaerobes, Enterobacteriaceae, at the expense of the obligate anaerobes, Ruminococcaceae (McDonald et al., 2018McDonald D. Hyde E. Debelius J.W. Morton J.T. Gonzalez A. Ackermann G. Aksenov A.A. Behsaz B. Brennan C. Chen Y. et al.American Gut ConsortiumAmerican Gut: an Open Platform for Citizen Science Microbiome Research.mSystems. 2018; 3: e00031-18Crossref PubMed Google Scholar). Among all tested media, mGAM cultures showed the lowest DJS divergence from PD, becoming increasingly similar to the original sample as growth proceeds (Figure S1A). Even at the single ASV level, mGAM cultures capture much of the diversity in PD (mGAM cultures have the highest Shannon diversity across all media, and the closest one to PD) (Figure 1C). In PD, there are 33 ASVs present above a relative abundance of 1%, 26 (79%) of which are present in mGAM day two culture. Overall, total shared ASVs between PD and mGAM day two account for 70% of the PD composition (by relative abundance), indicating that the mGAM culture recapitulates the bulk of the original community. Taken together, and consistent with previous reports showing that mGAM can support the growth of a wide variety of gut microorganisms in monoculture (Rettedal et al., 2014Rettedal E.A. Gumpert H. Sommer M.O. Cultivation-based multiplex phenotyping of human gut microbiota allows targeted recovery of previously uncultured bacteria.Nat. Commun. 2014; 5: 4714Crossref PubMed Scopus (71) Google Scholar, Tramontano et al., 2018Tramontano M. Andrejev S. Pruteanu M. Klünemann M. Kuhn M. Galardini M. Jouhten P. Zelezniak A. Zeller G. Bork P. et al.Nutritional preferences of human gut bacteria reveal their metabolic idiosyncrasies.Nat. Microbiol. 2018; 3: 514-522Crossref PubMed Scopus (75) Google Scholar), our results support the use of mGAM day two cultures as a viable ex vivo batch culturing model for the PD microbiome. With an optimized ex vivo culturing system for PD in hand, we next developed a combined biochemical and analytical chemistry approach to map the capacity of PD-derived microbial communities to metabolize clinically used, orally administered drugs (MDM-Screen) (Figure 2A). Three samples were prepared per drug of interest: (1) a 24-h mGAM ex vivo culture of PD, incubated with the drug of interest (final concentration 33 μM, in line with estimates of drug concentrations in the gastrointestinal tract) (Maier et al., 2018Maier L. Pruteanu M. Kuhn M. Zeller G. Telzerow A. Anderson E.E. Brochado A.R. Fernandez K.C. Dose H. Mori H. et al.Extensive impact of non-antibiotic drugs on human gut bacteria.Nature. 2018; 555: 623-628Crossref PubMed Scopus (629) Google Scholar), (2) a similar culture incubated with a vehicle control (DMSO), and (3) an equal volume of sterile mGAM, incubated with the same drug concentration. Cultures and controls were then incubated for an additional 24 h at 37°C in an anaerobic chamber, chemically extracted, and analyzed using high performance liquid chromatography coupled with mass spectrometry (HPLC-MS). To verify the reproducibility, the entire procedure was repeated three consecutive times. We tested a diverse library of 575 orally administered drugs, and although the majority of the drugs in this library are currently being used in the clinic, less than 10% of them had been previously explored with respect to MDM (Table S1A). A drug was deemed MDM+ when (1) a new metabolite was observed when incubated with PD culture or (2) the drug was no longer detected when incubated with PD culture, indicating that it is either consumed entirely or metabolized into a molecule that fails our detection, and (3) the drug was metabolized in the same manner during at least two of three independent experiments. Among the 575 drugs, we successfully analyzed 438 (76%); the remaining 137 failed MDM-Screen because of issues related to drug stability or incompatibilities with the extraction or chromatography methods employed (see Discussion). Of the successfully analyzed drugs, we identified 57 (13%) as MDM+. These spanned 28 pharmacological classes and even more based on their chemical structure (Figure 2B; Table S1B; Data S1). As expected, several previously reported MDM cases were identified. These include the nitroreduction of the muscle relaxant dantrolene (Kuroiwa et al., 1985Kuroiwa M. Inotsume N. Iwaoku R. Nakano M. [Reduction of dantrolene by enteric bacteria].Yakugaku Zasshi. 1985; 105: 770-774Crossref PubMed Scopus (2) Google Scholar), the antiepileptic clonazepam (Elmer and Remmel, 1984Elmer G.W. Remmel R.P. Role of the intestinal microflora in clonazepam metabolism in the rat.Xenobiotica. 1984; 14: 829-840Crossref PubMed Scopus (40) Google Scholar, Zimmermann et al., 2019bZimmermann M. Zimmermann-Kogadeeva M. Wegmann R. Goodman A.L. Separating host and microbiome contributions to drug pharmacokinetics and toxicity.Science. 2019; 363: eaat9931Crossref PubMed Scopus (118) Google Scholar), and the antihypertensive drug nicardipine (Kuroiwa et al., 1986Kuroiwa M. Inotsume N. Nakano M. [Reduction of nicardipine, calcium antagonist, with enteric bacteria].Yakugaku Zasshi. 1986; 106: 698-702Crossref PubMed Scopus (4) Google Scholar); hydrolysis of the isoxazole moiety in the antipsychotic risperidone (Mannens et al., 1993Mannens G. Huang M.L. Meuldermans W. Hendrickx J. Woestenborghs R. Heykants J. Absorption, metabolism, and excretion of risperidone in humans.Drug Metab. Dispos. 1993; 21: 1134-1141PubMed Google Scholar, Meuldermans et al., 1994Meuldermans W. Hendrickx J. Mannens G. Lavrijsen K. Janssen C. Bracke J. Le Jeune L. Lauwers W. Heykants J. The metabolism and excretion of risperidone after oral administration in rats and dogs.Drug Metab. Dispos. 1994; 22: 129-138PubMed Google Scholar); and azoreduction of the anti-inflammatory prodrug sulfasalazine (Azadkhan et al., 1982Azadkhan A.K. Truelove S.C. Aronson J.K. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.Br. J. Clin. Pharmacol. 1982; 13: 523-528Crossref PubMed Scopus (105) Google Scholar, Peppercorn and Goldman, 1972Peppercorn M.A. Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine.J. Pharmacol. Exp. Ther. 1972; 181: 555-562PubMed Google Scholar). More importantly, we identified a suite of novel MDM cases (45 cases, ∼80% of the MDM+ drugs): ten resulted from full depletion of the parent drug (or full conversion to a metabolite that evades our detection), while 35 resulted from the appearance of a new metabolite (Figures 2C and 2D; Table S1B; Data S1A). In most cases, the new metabolites showed a high-resolution mass spectrometry (HRMS) profile within a small difference from their parent drugs and/or a similar tandem MS fragmentation (HRMS/MS) pattern, indicating that they are derivatives (Wang et al., 2016Wang M. Carver J.J. Phelan V.V. Sanchez L.M. Garg N. Peng Y. Nguyen D.D. Watrous J. Kapono C.A. Luzzatto-Knaan T. et al.Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking.Nat. Biotechnol. 2016; 34: 828-837Crossref PubMed Scopus (1113) Google Scholar) (Table S1B; Data S1B). An aggregate statistical analysis of MDM+ and MDM− drugs revealed specific structural features that are significantly enriched in MDM+ drugs (e.g., a steroidal skeleton, nitro groups, ketones, among others) (see STAR Methods; Table S1C). Although HRMS and HRMS/MS analyses can narrow down the number of possibilities for the molecular structure of a given metabolite, they are not sufficient for full structural determination. Thus, we selected seven MDM+ examples for detailed characterization of their resulting metabolites: spironolactone (anti-hypertensive), tolcapone (anti-Parkinson’s), misoprostol (anti-ulcer), mycophenolate mofetil (immunosuppressant), capecitabine (anticancer), and finally, hydrocortisone and hydrocortisone acetate (two steroidal anti-inflammatory drugs that produced an identical MDM metabolite). In all but one example, no direct drug-microbiome interactions had been previously reported. The exception was hydrocortisone where several metabolites had been previously reported from individual gut isolates (Ridlon et al., 2013Ridlon J.M. Ikegawa S. Alves J.M. Zhou B. Kobayashi A. Iida T. Mitamura K. Tanabe G. Serrano M. De Guzman A. et al.Clostridium scindens: a human gut microbe with a high potential to convert glucocorticoids into androgens.J. Lipid Res. 2013; 54: 2437-2449Abstract Full Text Full Text PDF PubMed Scopus (103) Google Scholar, Winter et al., 1982Winter J. Cerone-McLernon A. O’Rourke S. Ponticorvo L. Bokkenheuser V.D. Formation of 20 β-dihydrosteroids by anaerobic bacteria.J. Steroid Biochem. 1982; 17: 661-667Crossref PubMed Scopus (21) Google Scholar), but the identity of the MDM metabolite we observed could not be accurately matched to any of them based on MS alone. To unequivocally determine the structure of the resulting metabolites, we isolated them from scaled-up biochemical incubations with PD cultures and elucidated their structures using nuclear magnetic resonance (NMR) and/or comparison to an authentic standard (STAR Methods; Data S2). For hydrocortisone, we determined that MDM results in the reduction of the ketone group at C20, producing 20β-dihydrocortisone. For hydrocortisone acetate, the same modification occurs but is accompanied with deacetylation of the C21 hydroxyl group (Figure S2). While C20 ketone reduction was previously reported for hydrocortisone (to produce either 20β-dihydrocortisone or 20α-dihydrocortisone depending on the gut isolate incubated with it; Ridlon et al., 2013Ridlon J.M. Ikegawa S. Alves J.M. Zhou B. Kobayashi A. Iida T. Mitamura K. Tanabe G. Serrano M. De Guzman A. et al.Clostridium scindens: a human gut microbe with a high potential to convert glucocorticoids into androgens.J. Lipid Res. 2013; 54: 2437-2449Abstract Full Text Full Text PDF PubMed Scopus (103) Google Scholar, Winter et al., 1982Winter J. Cerone-McLernon A. O’Rourke S. Ponticorvo L. Bokkenheuser V.D. Formation of 20 β-dihydrosteroids by anaerobic bacteria.J. Steroid Biochem. 1982; 17: 661-667Crossref PubMed Scopus (21) Google Scholar), neither MDM deacetylation nor C20 ketone reduction were reported for hydrocortisone acetate. For capecitabine, we show that MDM results in complete deglycosylation; for misoprostol and mycophenolate mofetil, we observed an ester hydrolysis transformation; and in the case of spironolactone, a thioester hydrolysis one. None of these MDM transformations were previously reported for these drugs. Finally, for tolcapone, we observed two consecutive transformations, a typical nitroreduction followed by a relatively uncommon N-acetylation—neither of which had been previously linked to the microbiome for this drug (Figure 2D). Taken together, these results establish MDM-Screen as a viable method for identifying both known and novel biochemical modifications of structurally and pharmacologically diverse drugs by the gut microbiome. Interestingly, based on already known pharmacokinetic studies in humans, some of these new MDM cases may have direct consequences on the activation or toxicity of the drugs involved. For example, in the case of spironolactone we observed the production of 7α-thiospironolactone, a postulated intermediate en route to the drug’s main active metabolite, 7α-thiomethylspironolactone (Gardiner et al., 1989Gardiner P. Schrode K. Quinlan D. Martin B.K. Boreham D.R. Rogers M.S. Stubbs K. Smith M. Karim A. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites.J. Clin. Pharmacol. 1989; 29: 342-347Crossref PubMed Scopus (93) Google Scholar, Sica, 2005Sica D.A. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis.Heart Fail. Rev. 2005; 10: 23-29Crossref PubMed Scopus (124) Google Scholar). For the prodrugs misoprostol and mycophenolate mofetil, we observed the production of their active metabolites misoprostol acid (Schoenhard et al., 1985Schoenhard G. Oppermann J. Kohn F.E. Metabolism and pharmacokinetic studies of misoprostol.Dig. Dis. Sci. 1985; 30: 126S-128SCrossref PubMed Scopus (52) Google Scholar, Tsai et al., 1991Tsai B.S. Kessler L.K. Stolzenbach J. Schoenhard G. Bauer R.F. Expression of gastric antisecretory and prostaglandin E receptor binding activity of misoprostol by misoprostol free acid.Dig. Dis. Sci. 1991; 36: 588-593Crossref PubMed Scopus (14) Google Scholar) and mycophenolic acid (Bullingham et al., 1998Bullingham R.E. Nicholls A.J. Kamm B.R. Clinical pharmacokinetics of mycophenolate mofetil.Clin. Pharmacokinet. 1998; 34: 429-455Crossref PubMed Scopus (692) Google Scholar), respectively. Interestingly, mycophenolic acid has been linked to the clinically observed gastrointestinal toxicity associated with mycophenolate mofetil use (Taylor et al., 2019Taylor M.R. Flannigan K.L. Rahim H. Mohamud A. Lewis I.A. Hirota S.A. Greenway S.C. Vancomycin relieves mycophenolate mofetil-induced gastrointestinal toxicity by eliminating gut bacterial β-glucuronidase activity.Sci Adv. 2019; 5: eaax2358Crossref PubMed Scopus (25) Google Scholar), albeit generated via a different route—hydrolysis of a biliary secreted glucuronide conjugate by gut microbiome-derived β-glucuronidases. Finally, in the case of tolcapone, N-acetylamino-tolcapone has been detected systemically in humans post-tolcapone administration and was suggested to be involved in liver toxicity observed clinically following tolcapone use, yet the mechanism of its production remains unknown (Jorga et al., 1999Jorga K. Fotteler B. Heizmann P. Gasser R. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase.Br. J. Clin. Pharmacol. 1999; 48: 513-520Crossref PubMed Scopus (72) Google Scholar, Smith et al., 2003Smith K.S. Smith P.L. Heady T.N. Trugman J.M. Harman W.D. Macdonald T.L. In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity.Chem. Res. Toxicol. 2003; 16: 123-128Crossref PubMed Scopus (109) Google Scholar). Our discovery that the same metabolite can be produced via MDM provides a possible explanation, and a potential link between the gut microbiome and tolcapone toxicity. In all four cases, additional experiments need to be performed to differentiate the contribution of human- and microbiome-derived metabolism to the observed drug pharmacokinetics and/or toxicity in humans. Next, we sought to expand our framework to accommodate multiple subjects. To accomplish this goal, we needed to first design a generalizable quantitative metric for assessing the best culturing medium for microbiome samples (Figures 3A and 3B ). In our analysis of PD’s ex vivo cultures, we applied a variety of metrics and found a medium that was the best trade-off between richness, evenness, and compositional similarity. However, this approach is not scalable to a large number of donors and also ignores the role of community biomass, which may lead to suboptimal media selection. Therefore, we developed a metric called Expected Number of Detectable Strains (ENDS), a corrected richness metric where the contribution of each ASV is weighed by the probability that its metabolite can be detected while considering total biomass (STAR Methods; Figure 3B; Methods S1). The core idea is that we desire a medium that supports the highest number of different bacterial ASVs, while ensuring that the metabolic contributions of these ASVs are detectable by our experimental method. ENDS utilizes two data inputs related to the ex vivo culture composition: relative abundance at a given taxonomic level and total community biomass;
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
蟹堡王完成签到 ,获得积分10
1秒前
jjjj1021完成签到,获得积分10
2秒前
3秒前
孙毅航完成签到,获得积分10
3秒前
浩浩发布了新的文献求助10
3秒前
Mint完成签到 ,获得积分10
4秒前
yating完成签到,获得积分10
4秒前
4秒前
lnvvl发布了新的文献求助20
5秒前
zhao完成签到,获得积分10
5秒前
丘比特的应助被王乐乐采纳,获得10
5秒前
6秒前
6秒前
尘南浔发布了新的文献求助10
6秒前
i3utter发布了新的文献求助10
6秒前
zink完成签到,获得积分10
6秒前
书不尽风月完成签到,获得积分10
7秒前
8秒前
小蘑菇的应助被毕业就摆烂采纳,获得10
8秒前
9秒前
everything完成签到,获得积分10
9秒前
9秒前
9秒前
在水一方的应助被小冯在努力采纳,获得10
9秒前
叶林海发布了新的文献求助10
10秒前
dawei发布了新的文献求助10
10秒前
10秒前
11秒前
11秒前
11秒前
小二郎的应助被ke采纳,获得10
12秒前
Ava的应助被SHN采纳,获得10
13秒前
染染来信完成签到,获得积分10
13秒前
13秒前
寻寻123发布了新的文献求助20
13秒前
王鹤谞完成签到,获得积分20
13秒前
17000416发布了新的文献求助10
14秒前
14秒前
zhikaiyici发布了新的文献求助30
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193653
求助须知:如何正确求助?哪些是违规求助? 9579816
关于积分的说明 21867585
捐赠科研通 7793288
什么是DOI,文献DOI怎么找? 3437343
关于科研通互助平台的介绍 2560779
邀请新用户注册赠送积分活动 2484193